MCM
TVRD

Moore Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Moore Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,783
Closed -$1.22M – 427
2015
Q2 		$1.22M Buy
+2,783
New +$1.08M 0.03% 349

Other funds holding TVRD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Moore Capital Management's TVRD Position: Q3 2015 in Review

Moore Capital Management sold out of Tvardi Therapeutics (TVRD) in Q3 2015, closing a stake of 2,783 shares — an estimated $1.22M sold.

Moore Capital Management first reported a position in TVRD in Q2 2015 and held it in 1 quarter. The position peaked at $1.22M in Q2 2015. 92 funds tracked by Wall St. Rank hold TVRD as of Q3 2015.

  • Moore Capital Management reported no remaining Tvardi Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Moore Capital Management sold 2,783 Tvardi Therapeutics shares in Q3 2015, an estimated $1.22M.
  • Moore Capital Management first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 1 quarter.
  • Moore Capital Management's Tvardi Therapeutics position peaked at $1.22M in Q2 2015.
  • 92 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2015.

Based on Moore Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.